Source comparison
AOD 9604 vs hGH vs Other Lipolytic Peptides
AOD 9604 Beta-3 adrenergic agonism Beta-3 adrenergic receptor None Neutral Isolated lipolysis studies without growth confounders hGH (191aa) GH receptor activation → JAK2-STAT5 → IGF-1 synthesis Growth hormone receptor Significant (2-3× baseline) Hyperglycaemi
This comparison does not assign a generated winner or score.
- AOD 9604
- Beta-3 adrenergic agonism
- Beta-3 adrenergic receptor
- None
- Neutral
- Isolated lipolysis studies without growth confounders
- hGH (191aa)
- GH receptor activation → JAK2-STAT5 → IGF-1 synthesis
- Growth hormone receptor
- Significant (2-3× baseline)
- Hyperglycaemic (insulin resistance)
- Anabolic signalling, IGF-1 pathway research
- CJC-1295
- GHRH analogue → pulsatile GH release
- GHRH receptor (pituitary)
- Moderate (pulsatile)
- Variable (depends on GH response)
- Physiological GH pulsatility models
- Hexarelin
- Ghrelin receptor agonist → GH secretion
- GHSR-1a (ghrelin receptor)
- Moderate
- Orexigenic (appetite stimulation)
- Ghrelin pathway and appetite regulation studies
- Ipamorelin
- Selective ghrelin receptor agonist
- GHSR-1a
- Mild
- Minimal
- GH secretagogue research with low side-effect profile
- Bottom Line
- AOD 9604 is the only option in this table that stimulates fat breakdown without activating growth hormone pathways. Making it ideal for lipolysis-specific protocols where IGF-1 or glucose confounders would invalidate results.